Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Weber, T; Horn, S; Slany, J; Watschinger, B; Wenzel, RR; Zweiker, R.
The SPRINT-Study (Systolic Blood Pressure Intervention Trial) - Do we now need to describe the Guidelines? Opinion of the Austrian Society of Hypertensiology (OEGH)
J HYPERTON. 2016; 20(1): 16-20.
Web of Science
- Co-authors Med Uni Graz
- Horn Sabine
- Zweiker Robert
- Altmetrics:
- Abstract:
- In the recently published SPRINT trial, patients were randomly assigned to a systolic blood pressure goal of less than 120 mmHg (intensive therapy) or less than 140 mmHg (standard therapy). The trial was prematurely terminated at 3.26 years owing to a significantly lower rate of the primary composite outcome (myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes) in the intensive-treatment group (relative risk reduction 25%, NNT 61). All-cause mortality was also significantly lower in the intensive treatment group (relative risk reduction 27%, NNT 90). Serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, occured more frequently in the intensive treatment group. Of note, office blood pressure was measured automatically after 5 minutes of rest, without a physician being present. In addition, testing for orthostatic blood pressure fall was mandatory. Patient groups not included in the trial were diabetics, patients younger than 50 years of age, patients with a prior stroke, and those with heart failure. Based on previous evidence and on the findings from SPRINT, the Austrian Society of Hypertension recommends a systolic blood pressure of below 130 mmHg (blood pressure target 120 mmHg) in SPRINT-like patients, who can tolerate lower blood pressure levels.
- Find related publications in this database (Keywords)
- Sprint trial
- blood pressure goals
- cardiovascular events
- office blood pressure monitoring